Clinical experience of recombinant human erythropoietin in uremic children: Report of three cases

F. R. Chuang, M. S. Wu, M. L. Leu, C. C. Huang

Research output: Contribution to journalArticle

Abstract

Anemia due to decreased erythropoietin production is one of the major complications in uremic patients. The aim of the study is to evaluate the clinical efficiency and safety of rHuEPO in the treatment of anemia in uremic children receiving regular hemodialysis. Three uremic children, age 8, 12, and 14 year-old, under maintenance hemodialysis with hematocrit (Hct) value lower than 20% were observed for 6 months. rHuEPO 50 u/kg were given intravenously three times a week initially. Hct value of 30% was the target of the therapy. All 3 children responded to the therapy and reached the target Hct value within 11 to 18 weeks. They received no further transfusion after the therapy. The maintenance dose to keep Hct value around 30% is 75 to 120 u/kg/wk. The serum biochemistry examination showed no difference before and after the therapy. The physical endurance, bodyweight and height increased in all children. The left ventricular end-diastolic dimension in echocardiography decreased and the ejection fraction increased after 6 months of the treatment. Serum ferritin concentrations decreased in all children. Mild hypertension developed in one child. Heparin dose was increased when the target Hct value was around 30% in 2 children. We suggested that low dose rHuEPO therapy was safe and effective in uremic children, but close monitoring for the development of hypertension and iron deficiency was mandatory.

Original languageEnglish
Pages (from-to)71-76
Number of pages6
JournalChang Gung Medical Journal
Volume19
Issue number1
Publication statusPublished - 1996
Externally publishedYes

Fingerprint

Erythropoietin
Hematocrit
Therapeutics
Renal Dialysis
Anemia
Physical Endurance
Hypertension
Ferritins
Serum
Biochemistry
Echocardiography
Heparin
Iron
Maintenance
Safety

Keywords

  • children
  • hemodialysis
  • recombinant human erythropoietin
  • uremia

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Clinical experience of recombinant human erythropoietin in uremic children : Report of three cases. / Chuang, F. R.; Wu, M. S.; Leu, M. L.; Huang, C. C.

In: Chang Gung Medical Journal, Vol. 19, No. 1, 1996, p. 71-76.

Research output: Contribution to journalArticle

@article{8c512532d10f47919de0c5dad6c084aa,
title = "Clinical experience of recombinant human erythropoietin in uremic children: Report of three cases",
abstract = "Anemia due to decreased erythropoietin production is one of the major complications in uremic patients. The aim of the study is to evaluate the clinical efficiency and safety of rHuEPO in the treatment of anemia in uremic children receiving regular hemodialysis. Three uremic children, age 8, 12, and 14 year-old, under maintenance hemodialysis with hematocrit (Hct) value lower than 20{\%} were observed for 6 months. rHuEPO 50 u/kg were given intravenously three times a week initially. Hct value of 30{\%} was the target of the therapy. All 3 children responded to the therapy and reached the target Hct value within 11 to 18 weeks. They received no further transfusion after the therapy. The maintenance dose to keep Hct value around 30{\%} is 75 to 120 u/kg/wk. The serum biochemistry examination showed no difference before and after the therapy. The physical endurance, bodyweight and height increased in all children. The left ventricular end-diastolic dimension in echocardiography decreased and the ejection fraction increased after 6 months of the treatment. Serum ferritin concentrations decreased in all children. Mild hypertension developed in one child. Heparin dose was increased when the target Hct value was around 30{\%} in 2 children. We suggested that low dose rHuEPO therapy was safe and effective in uremic children, but close monitoring for the development of hypertension and iron deficiency was mandatory.",
keywords = "children, hemodialysis, recombinant human erythropoietin, uremia",
author = "Chuang, {F. R.} and Wu, {M. S.} and Leu, {M. L.} and Huang, {C. C.}",
year = "1996",
language = "English",
volume = "19",
pages = "71--76",
journal = "Chang Gung Medical Journal",
issn = "0255-8270",
publisher = "Chang Gung Medical Journal",
number = "1",

}

TY - JOUR

T1 - Clinical experience of recombinant human erythropoietin in uremic children

T2 - Report of three cases

AU - Chuang, F. R.

AU - Wu, M. S.

AU - Leu, M. L.

AU - Huang, C. C.

PY - 1996

Y1 - 1996

N2 - Anemia due to decreased erythropoietin production is one of the major complications in uremic patients. The aim of the study is to evaluate the clinical efficiency and safety of rHuEPO in the treatment of anemia in uremic children receiving regular hemodialysis. Three uremic children, age 8, 12, and 14 year-old, under maintenance hemodialysis with hematocrit (Hct) value lower than 20% were observed for 6 months. rHuEPO 50 u/kg were given intravenously three times a week initially. Hct value of 30% was the target of the therapy. All 3 children responded to the therapy and reached the target Hct value within 11 to 18 weeks. They received no further transfusion after the therapy. The maintenance dose to keep Hct value around 30% is 75 to 120 u/kg/wk. The serum biochemistry examination showed no difference before and after the therapy. The physical endurance, bodyweight and height increased in all children. The left ventricular end-diastolic dimension in echocardiography decreased and the ejection fraction increased after 6 months of the treatment. Serum ferritin concentrations decreased in all children. Mild hypertension developed in one child. Heparin dose was increased when the target Hct value was around 30% in 2 children. We suggested that low dose rHuEPO therapy was safe and effective in uremic children, but close monitoring for the development of hypertension and iron deficiency was mandatory.

AB - Anemia due to decreased erythropoietin production is one of the major complications in uremic patients. The aim of the study is to evaluate the clinical efficiency and safety of rHuEPO in the treatment of anemia in uremic children receiving regular hemodialysis. Three uremic children, age 8, 12, and 14 year-old, under maintenance hemodialysis with hematocrit (Hct) value lower than 20% were observed for 6 months. rHuEPO 50 u/kg were given intravenously three times a week initially. Hct value of 30% was the target of the therapy. All 3 children responded to the therapy and reached the target Hct value within 11 to 18 weeks. They received no further transfusion after the therapy. The maintenance dose to keep Hct value around 30% is 75 to 120 u/kg/wk. The serum biochemistry examination showed no difference before and after the therapy. The physical endurance, bodyweight and height increased in all children. The left ventricular end-diastolic dimension in echocardiography decreased and the ejection fraction increased after 6 months of the treatment. Serum ferritin concentrations decreased in all children. Mild hypertension developed in one child. Heparin dose was increased when the target Hct value was around 30% in 2 children. We suggested that low dose rHuEPO therapy was safe and effective in uremic children, but close monitoring for the development of hypertension and iron deficiency was mandatory.

KW - children

KW - hemodialysis

KW - recombinant human erythropoietin

KW - uremia

UR - http://www.scopus.com/inward/record.url?scp=0029933092&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029933092&partnerID=8YFLogxK

M3 - Article

C2 - 8935379

AN - SCOPUS:0029933092

VL - 19

SP - 71

EP - 76

JO - Chang Gung Medical Journal

JF - Chang Gung Medical Journal

SN - 0255-8270

IS - 1

ER -